Browse the evidence

Tirzepatide significantly reduced body weight, BMI, and waist circumference compared with placebo.

Tirzepatide may be an effective treatment for reducing body weight and improving BMI in Chinese adults.

Ecnoglutide produced mean weight loss of –9.9% (1.2 mg), –13.3% (1.8 mg), and –15.4% (2.4 mg) from baseline at 48 weeks, compared with –0.3% with placebo.

Ecnoglutide is effective for weight loss in Asian populations.

78%–93% of participants achieved ≥5% weight reduction with ecnoglutide.

A significant proportion of users can expect meaningful weight loss.

Weight-reduced patients lost 7.2% total body weight (TBW) versus 10.3% in non-weight-reduced patients (p < 0.001).

Practitioners should consider weight-reduction status when evaluating weight loss outcomes with tirzepatide.

Patients switching from semaglutide due to plateau lost 8.1% TBW versus 2.9% for non-responders (p < 0.001).

Switching from semaglutide may yield different weight loss results based on prior response.

Consuming protein three times a day results in an increase in lean mass of 1.15 kg after 8 weeks of resistance training.

Practitioners can recommend three protein meals per day to support muscle gain.

Consuming protein five times a day results in an increase in lean mass of 0.63 kg after 8 weeks of resistance training.

Practitioners can recommend five protein meals per day to support muscle gain.

Daily protein intake in patients' usual diets was below the recommended levels.

It is important to assess and address protein intake in patients with chronic lung disease.

The optimal SPAN combination of 8.0-9.4 h/day sleep, 42-104 min/day MVPA, and a DQS of 32.5-50.0 was associated with a 57% lower risk of major adverse cardiovascular events (MACE) (HR: 0.43; 95% CI: 0.30, 0.62).

Practitioners should encourage optimal sleep, physical activity, and nutrition combinations to reduce cardiovascular event risk.

A minimum combined variation of an additional 11 min/day of sleep, 4.5 min/day MVPA, and 3 DQS points was associated with 10% lower MACE risk (HR: 0.90; 0.88, 0.94).

Small improvements in sleep, activity, and diet can significantly reduce cardiovascular event risk.

Progressive overload, intensity management, and flexible dieting are more effective and sustainable than other methods.

Practitioners should focus on progressive overload and flexible dieting for better results.

Cardiovascular training, when properly integrated, does not hinder muscle growth.

Incorporating cardiovascular training can be beneficial without compromising muscle growth.

Higher adherence to whole food plant-based (WFPB) and vegan diets is significantly associated with lower BMI.

Encouraging adherence to WFPB and vegan diets may help individuals achieve lower body weight.

Fully plant-based diets (WFPB and vegan) have the healthiest Healthy Eating Index (HEI) scores and BMIs.

Promoting fully plant-based diets may lead to improved diet quality and health outcomes.

AOM use prior to BMS is associated with significantly higher weight loss until the day of surgery (1.37 vs. 0.05; p = 0.04).

Practitioners may consider AOMs as a beneficial preoperative strategy for weight loss in bariatric surgery candidates.

Lifestyle therapies, including weight loss and diet, are effective for managing obesity-related hypertension.

Encouraging weight loss and dietary changes can be beneficial for patients with obesity-related hypertension.

New dietary interventions are poised to overtake traditional strategies as the ideal approach to achieving sustained weight loss for obesity-associated hypertension patients.

Practitioners should consider implementing new dietary interventions for better weight loss outcomes in patients.

Obesity has been associated with an increased risk of all-cause and cardiovascular mortality.

Awareness of the mortality risks associated with obesity is essential for patient management.

Lessened emotional eating is significantly associated with concurrent reductions in weight and waist circumference.

Reducing emotional eating can be an effective strategy for achieving weight loss and waist circumference reduction.

Median time to maintenance was significantly shorter for Tirzepatide (32 days) than Semaglutide (143 days).

Practitioners may prefer Tirzepatide for quicker dose optimization.

Obesity medications (OMs) produce meaningful weight loss (∼5%-24%) and improve cardiometabolic health.

Practitioners can expect significant weight loss and health benefits from OMs.

At 15 months, total body weight loss (TBWL) was greater in mild versus severe IMS groups (14.8% vs. 11.0%, p = 0.015).

Clinicians should consider IMS severity when predicting weight loss outcomes with tirzepatide.

The proportion achieving ≥ 20% TBWL was nearly two-fold higher in mild versus severe IMS (27% vs. 14%, p = 0.03).

Higher IMS severity is associated with lower chances of achieving significant weight loss with tirzepatide.

The nutritional guidance-only group experienced the most pronounced reduction in body mass.

Nutritional guidance alone can lead to significant weight loss in overweight and obese women.